User profiles for Andreas M. Schmitt

Andreas Michael Schmitt

Department of Medical Oncology, University Hospital Basel, Basel, Switzerland
Verified email at usb.ch
Cited by 1365

[HTML][HTML] Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

C Axfors, AM Schmitt, P Janiaud, J Van't Hooft… - Nature …, 2021 - nature.com
Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs)
on hydroxychloroquine/chloroquine, which currently face recruitment challenges or …

[HTML][HTML] Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

…, KA Wilkinson, M Wu, F Byrne, M Cerrone, AM Schmitt… - Nature cancer, 2021 - nature.com
Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring
(CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in …

[HTML][HTML] Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis

…, C Axfors, AM Schmitt, V Gloy, F Ebrahimi, M Hepprich… - Jama, 2021 - jamanetwork.com
Importance Convalescent plasma is a proposed treatment for COVID-19. Objective To assess
clinical outcomes with convalescent plasma treatment vs placebo or standard of care in …

[HTML][HTML] Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer

…, STC Shepherd, L Au, M Wu, R Harvey, AM Schmitt… - The Lancet, 2022 - thelancet.com
Patients with cancer are at greater risk of severe COVID-19 and have been prioritised for
COVID-19 vaccination globally. We previously showed that following two doses of COVID-19 …

[PDF][PDF] Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer

…, STC Shepherd, L Au, KA Wilkinson, M Wu, AM Schmitt… - Cancer Cell, 2022 - cell.com
Patients with cancer are at higher risk of severe COVID-19 (Grivas et al., 2021; Kuderer et al.,
2020), and they are currently prioritized globally for a third COVID-19 vaccine dose. …

Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways

…, R Wardenaar, DCJ Spierings, C Spencer, AM Schmitt… - Cancer discovery, 2023 - AACR
Despite treatment advances, melanoma remains a deadly disease at stage IV. Through research
autopsy and dense sampling of metastases combined with extensive multiomic profiling…

[HTML][HTML] Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical …

C Axfors, P Janiaud, AM Schmitt, J van't Hooft… - BMC infectious …, 2021 - Springer
Background Convalescent plasma has been widely used to treat COVID-19 and is under
investigation in numerous randomized clinical trials, but results are publicly available only for a …

[HTML][HTML] Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

…, S Caidan, M Howell, M Wu, R Goldstone, M Crawford… - Nature Cancer, 2021 - nature.com
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the
prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. …

Clinical trial evidence supporting US food and drug administration approval of novel cancer therapies between 2000 and 2016

A Ladanie, AM Schmitt, B Speich, F Naudet… - JAMA network …, 2020 - jamanetwork.com
Importance Clinical trial evidence used to support drug approval is typically the only information
on benefits and harms that patients and clinicians can use for decision-making when …

[PDF][PDF] Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer

…, L Au, M Wu, R Harvey, KA Wilkinson, AM Schmitt… - Cell Reports …, 2022 - cell.com
Patients with blood cancer continue to have a greater risk of inadequate immune responses
following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the …